Patent Watch: Have the Biosimilar Floodgates Been Opened in the United States?

30 April 2015 Nature Reviews Publication
Authors: Courtenay C. Brinckerhoff Kristel Schorr

Nature Reviews

Partners Courtenay Brinckerhoff and Kristel Schorr contributed an article to Nature Reviews, “Patent Watch: Have the Biosimilar Floodgates Been Opened in the United States?” on April 30, 2015. The article discussed the first US Food and Drug Administration’s first approval of a biosimilar product and the regulatory hurdles products must clear before entering the US market.

Related Services

Insights

Expectation Maximization in Patent Application Disclosures: Considerations with AI-Related Inventions
05 June 2020
Privacy, Cybersecurity & Technology Law Perspectives
Rams Jerseys "Sew" Seeds for Uniform Ads
04 June 2020
Legal News: Sports & Entertainment
Tackling Legal and Business Challenges Caused by the COVID-19 Pandemic
04 June 2020
Coronavirus Resource Center
The Long Arm of American Enforcement: How Companies Without U.S. Operations Can Still Find Themselves Facing U.S. Law and Regulatory Enforcement
04 June 2020
Legal News: Government Enforcement, Defense & Investigations